Clinical and economic analysis of empagliflozin therapy in patients with heart failure across the ejection fraction range
Aim. To evaluate the cost-effectiveness of empagliflozin therapy in patients with heart failure (HF) across the ejection fraction (EF) range in the Russian Federation.Material and methods. An analysis of the cost of HF management was carried out and an analytical decision-making model was built in...
Saved in:
| Main Authors: | S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Lutova, E. A. Popova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2023-07-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/5475 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis
by: S. V. Nedogoda, et al.
Published: (2019-10-01) -
Comparison of the effects of metformin and empagliflozin on cardiac function in heart failure with preserved ejection fraction mice
by: Xiehong Liu, et al.
Published: (2025-04-01) -
Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria
by: S. V. Nedogoda, et al.
Published: (2019-07-01) -
Cost-utility analysis of empagliflozin compared with dapagliflozin in patients with type 2 diabetes in China
by: Huiyuan Zhang, et al.
Published: (2025-07-01) -
Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis
by: Qingkai Yan, et al.
Published: (2024-11-01)